EVALUATION OF VASOSTATIN, AN INHIBITOR OF ANGIOGENESIS, AS A POTENTIAL CANCER THERAPEUTIC.
Commerce Business Daily
EVALUATION OF VASOSTATIN, AN INHIBITOR OF ANGIOGENESIS, AS A POTENTIAL CANCER
THERAPEUTIC.
National Cancer Institute Technology Transfer Branch CRADA Opportunity
Announcement Summary: The National Cancer Institute (NCI) is currently
seeking a Collaborator for a Cooperative Research and Development
Agreement (CRADA) to work with investigators in the Experimental
Transplantation and Immunology Branch to study vasostatin, an inhibitor
of angiogenesis, and evaluate its potential as a cancer therapeutic.
Proposed NCI Contribution: Expertise in the field of angiogenesis and in
the biological and biochemical properties of vasostatin, a calreticulin
fragment that inhibits endothelial cell proliferation in vitro,
angiogenesis and tumor growth in vivo. NCI would provide the bacteria
expressing the active molecule, active fragments and inactive mutants,
and methods for purification. NCI would also provide information on the
surface receptor for the molecule and its signaling as this information
becomes available through continuing laboratory investigation. Proposed
CRADA Collaborator Contribution: The CRADA Collaborator would provide
highly purified protein produced under GLP conditions to support the NCI
laboratory. Collaborator would work with the NCI laboratory to further
develop the drug as a cancer therapeutic for human use. This would
include preclinical and laboratory studies designed to identify the cell
surface receptor for vasostatin and clarifying its downstream signaling,
as well as studies in pre-clinical animal models. Proposed Joint
Contribution: NCI and the Collaborator will jointly design a CRADA
Research Plan and will jointly interpret the data generated under the
research plan. Selection Criteria for Choosing the CRADA Collaborator May
Include: 1. A demonstrated background and expertise in recombinant
protein manufacturing. 2. A demonstrated record of success in the
commercial development and production of products related to this area of
technology. 3. The demonstration of adequate resources to assist in this
collaboration and to perform the research and development necessary for
commercialization of the resulting inventions. 4. The willingness to
commit best effort and demonstrated resources to the research and
development of vasostatin and/or one or more of its fragments. 5. The
level of financial and staffing support the CRADA Collaborator will
provide for CRADA-related activities. 6. The willingness to cooperate
with the NCI in the timely publication of research results. 7. The
agreement to be bound by the appropriate Department of Health and Human
Services (DHHS) regulations relating to human subject research and to all
Public Health Service (PHS) policies relating to the use and care of
laboratory animals. 8. The willingness to accept the legal provisions and
language of the CRADA. These provisions govern the distribution of future
patent rights to CRADA inventions. Generally, the rights of ownership are
retained by the organization that is the employer of the inventor with
(1) the grant of a license for research and other Government purposes to
the Government whenthe CRADA Collaborator's employee is the sole
inventor, or (2) the grant of an option to elect an exclusive or
nonexclusive license to the CRADA Collaborator when the Government
employee is the sole inventor. Response Procedure: Interested parties
should notify the Technology Transfer Branch of the NCI in writing of
their interest in the CRADA collaboration no later than December 6, 2001.
The written notice should briefly address the selection criteria listed
above. Contact Information: CRADA Contact: Suzanne M. Frisbie, Ph.D. 6120
Executive Boulevard, Suite 450 Rockville, Maryland 20852 Phone:
301-496-0477 Fax: 301-402-2117 Email: Fris...@otd.nci.nih.gov WEB: Click
here to view the standard NIH CRADA document.,
http://ttb.nci.nih.gov/forms.html. E-MAIL: Click here to send a message
to the CRADA point of, Fris...@otd.nci.nih.gov. Posted 11/02/01
(W-SN5121O9).